Results 211 to 220 of about 11,407 (242)
Some of the next articles are maybe not open access.
Biosimilars: Are They Bioequivalent?
Digestive Diseases, 2014Biologics have revolutionized several areas of medical therapeutics, and dozens of them are used by millions of patients. Monoclonal antibodies are only one type of biologics, but more than 900 are now in different phases of development. These drugs are complex to make and not cheap.
openaire +2 more sources
Biosimilars 101: An Introduction to Biosimilars
2018The surging costs of biological medicines worldwide have necessitated the development of biosimilars. These highly similar versions of off-patent biological products entered the EU in 2006 and the U.S. in 2015. Unlike small molecule generic drugs, which are chemically identical to their originator products, biosimilar products cannot be identical ...
openaire +1 more source
2017
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma +2 more
openaire +1 more source
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma +2 more
openaire +1 more source
Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity
Eye, 2022Ashish Sharma +4 more
openaire +3 more sources
Biosimilars accessible in the market for the treatment of cancer
Journal of Controlled Release, 2021Neelima Anup +2 more
exaly
Biosimilars in Belgium: a proposal for a more competitive market
Acta Clinica Belgica, 2021Evelien Moorkens +2 more
exaly
The Coming of Age of Biosimilars: A Personal Perspective
Biologics, 2022Sarfaraz K Niazi, Niazi Sarfaraz K
exaly
Biosimilars. Was für Arzneimittel sind Biosimilars?
2019Kurzinformation für ...
openaire +1 more source
Nocebo effect and biosimilars in inflammatory bowel diseases: what’s new and what’s next?
Expert Opinion on Biological Therapy, 2021Ferdinando D´Amico +2 more
exaly